DBT and Escitalopram in Borderline Personality Disorder

The recruitment status of this study is unknown because the information has not been verified recently.

Verified November 2005 by Bronx VA Medical Center. Recruitment status was Recruiting

First Received on November 17, 2005. No Changes Posted

Sponsor:	Bronx VA Medical Center
Information provided by:	Bronx VA Medical Center
ClinicalTrials.gov Identifier:	NCT00255554

Purpose

Subjects will receive six months of DBT, consisting of one 90-minute group and one 60-minute individual session per week as well as telephone availability of the individual therapist. Half the subjects will concurrently receive escitalopram while half will receive placebo, in a randomized double-blind design.

Condition	Intervention
Borderline Personality Disorder	Behavioral: Dialectical Behavioral Therapy Drug: Escitalopram

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment
Official Title:	Effects of Dialectical Behavioral Therapy and Escitalopram on Impulsive Aggression, Affective Instability and Cognitive Processing in Borderline Personality Disorder

Resource links provided by NLM:

MedlinePlus related topics: Personality Disorders

Drug Information available for: Benzetimide Dexetimide Citalopram hydrobromide Citalopram Escitalopram Escitalopram oxalate

U.S. FDA Resources

Further study details as provided by Bronx VA Medical Center:

Primary Outcome Measures:

Measures of impulsivity, aggression, affective impulsivity, immediate and delayed memory, and cognitive processing at baseline, 6 months and 9 months

Eligibility

Ages Eligible for Study:	18 Years to 60 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria: Is a male or female between 18 and 60 who meets criteria for Borderline Personality Disorder and has been off psychotropic medications for at least 2 weeks (6 weeks for fluoxetine).

Exclusion Criteria: Meets criteria for Schizophrenia, Bipolar Disorder, Mental Retardation, current or recent Substance Dependence or a current Major Depressive Episode. Subjects also should not currently be in individual psychotherapy. (Case management and work therapy programs are allowed.)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00255554

Contacts

Contact: Emily Hart

212-241-0441

mpgroup@mssm.edu

Locations

United States, New York
Bronx VA Medical Center	Recruiting
Bronx, New York, United States, 10029

Sponsors and Collaborators

Bronx VA Medical Center

Investigators

Principal Investigator:

Marianne Goodman, MD

Bronx VA Medical Center/Mount Sinai School of Medicine

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00255554 History of Changes
Other Study ID Numbers:	3277-03-0027
Study First Received:	November 17, 2005
Last Updated:	November 17, 2005
Health Authority:	United States: Federal Government

Keywords provided by Bronx VA Medical Center:

Borderline Personality Disorder
BPD
Dialectical Behavior Therapy

DBT
Escitalopram
Lexapro

Additional relevant MeSH terms:

Personality Disorders
Borderline Personality Disorder
Mental Disorders
Dexetimide
Citalopram
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Parasympatholytics
Autonomic Agents
Peripheral Nervous System Agents

Physiological Effects of Drugs
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Serotonin Agents

ClinicalTrials.gov processed this record on February 09, 2012